CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Confocal laser endomicroscopy (CLE) — Coverage Criteria

Policy on coverage and medical necessity of confocal laser endomicroscopy (CLE) as an adjunct to endoscopy for gastrointestinal and selected non-gastrointestinal indications for Blue Cross Blue Shield - Rhode Island members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyConfocal laser endomicroscopy (CLE) — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionClaims for CLE using codes 43206, 43252, 88375, and 0397T will be denied or considered not medically necessary for Commercial products and not covered for Medicare due to insufficient evidence.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2FDA-cleared CLE system types

4Not covered procedure codes

insufficientEvidence conclusion

limitedLimitations

Coverage and Medical Necessity Determinations

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage determinations

Covered when ALL of the following are met:

BlueCHiP for Medicare stance: Use of confocal laser endomicroscopy is not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.

Commercial Products stance: Use of confocal laser endomicroscopy is considered not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes.

The following procedure and reporting codes are not covered / not medically necessary: 43206 (Esophagoscopy, flexible, transoral; with optical endomicroscopy), 43252 (Esophagogastroduodenoscopy, flexible, transoral; with optical endomicroscopy), 88375 (Optical endomicroscopic image(s), interpretation and report, real-time or referred, each endoscopic session), and 0397T (Endoscopic retrograde cholangiopancreatography (ERCP), with optical endomicroscopy — list separately in addition to code for primary procedure).

For Commercial Products, confocal laser endomicroscopy (CLE) is considered not medically necessary. For BlueCHiP for Medicare, CLE is not covered. This determination is based on an overall conclusion that the evidence is insufficient to determine the effects of the technology on health outcomes and is not adequate to replace standard biopsy-based diagnostic or surveillance strategies.

Clinical studies, including randomized trials and meta-analyses, have reported increased sensitivity for detecting dysplasia in some settings (for example, Barrett esophagus), but pooled diagnostic performance and trial outcomes have not demonstrated consistent, high enough accuracy or patient-outcome benefit to change established surveillance recommendations. Consequently, CLE is not considered to have demonstrated sufficient impact on health outcomes to support coverage or medical necessity.

Procedure and Billing Codes

Not covered / Not medically necessary CLE procedure codesCPT | HCPCSNot Covered

43206	Esophagoscopy, flexible, transoral; with optical endomicroscopy
43252	Esophagogastroduodenoscopy, flexible, transoral; with optical endomicroscopy
88375	Optical endomicroscopic image(s), interpretation and report, real-time or referred, Each endoscopic session
0397T	Endoscopic retrograde cholangiopancreatography (ERCP), with optical endomicroscopy (List separately in addition to code for primary procedure)

Actions, Authorization, and Billing Guidance for Providers

Prior Authorization

Prior authorization

Prior authorization is not applicable.

Step Therapy

Step therapy

No step therapy requirements specified.

Documentation Required

Benefit and member documentation

Refer to the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for member-specific coverage. Benefits may vary between groups and contracts; for member-specific benefits or eligibility, contact the provider call center.

Denial Risk

Denial triggers

Claims for confocal laser endomicroscopy (CLE) will be denied or considered not medically necessary for Commercial Products and not covered for BlueCHiP for Medicare. The following codes are not covered for BlueCHiP for Medicare and not medically necessary for Commercial Products:

43206 Esophagoscopy, flexible, transoral; with optical endomicroscopy
43252 Esophagogastroduodenoscopy, flexible, transoral; with optical endomicroscopy
88375 Optical endomicroscopic image(s), interpretation and report, real-time or referred; each endoscopic session
0397T Endoscopic retrograde cholangiopancreatography (ERCP), with optical endomicroscopy (List separately in addition to code for primary procedure)

Clinical Background and Evidence Summary

Confocal laser endomicroscopy (CLE) is an in vivo microscopic imaging technique performed during endoscopy that uses a low‑power laser and confocal detection to visualize mucosal cellular structures and has been proposed as a real‑time alternative or adjunct to biopsy/polypectomy for characterizing lesions and targeting biopsies.

Two CLE system types have been cleared by FDA (endoscope‑based and probe‑based); both use contrast (typically intravenous fluorescein), have a relatively small viewing area and limited depth of view, and while diagnostic accuracy studies and some randomized trials exist, the available evidence is insufficient to determine whether CLE improves health outcomes or can replace standard histopathologic surveillance protocols.

Definitions and Device Types

Confocal laser endomicroscopy (CLE) — definition and alternate names

Primary definitionIn vivo microscopic imaging technique during endoscopy that uses a low-power laser and a pinhole-based confocal detection system to visualize mucosal cellular structures (also called confocal fluorescent endomicroscopy or optical endomicroscopy).

Purpose / clinical useProposed as a real-time alternative to biopsy/polypectomy and histopathologic analysis and to target areas for biopsy in conditions such as colorectal lesions, inflammatory bowel disease, and Barrett esophagus.

Imaging mechanismIllumination with a low‑power laser and detection through the same lens via a pinhole to exclude out-of-focus light and increase image resolution.

Contrast agentTypically optimized using a contrast agent; the most widely used is intravenous fluorescein (FDA‑approved for ophthalmologic imaging).

Regulatory noteTwo CLE systems have been cleared by the U.S. FDA through the 510(k) process (endoscope-based and probe-based).

Endoscope-based vs probe-based CLE — differences in depth and viewing area

Endoscope-based CLEConfocal probe is incorporated onto the tip of a conventional endoscope; depth of view up to ~250 μm and viewing area up to ~700 μm.

Probe-based CLEA fiber‑optic probe is passed through the endoscope biopsy channel; depth of view about ~120 μm and a smaller viewing area than endoscope-based systems.

Practical implicationBoth system types have limited depth and small viewing areas, emphasizing the need for careful conventional endoscopic targeting of areas for evaluation.

Examples (FDA-cleared)Endoscope-based: Confocal Video Colonoscope (Pentax). Probe-based: Cellvizio® (Mauna Kea Technologies).